| 1.32 -0.05 (-3.65%) | 04-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 1.62 |
1-year : | 1.86 |
| Resists | First : | 1.39 |
Second : | 1.6 |
| Pivot price | 1.37 |
|||
| Supports | First : | 1.05 |
Second : | 0.88 |
| MAs | MA(5) : | 1.41 |
MA(20) : | 1.35  |
| MA(100) : | 1.12 |
MA(250) : | 1.08 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 38.7 |
D(3) : | 50.8 |
| RSI | RSI(14): 50.4 |
|||
| 52-week | High : | 1.69 | Low : | 0.46 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ CNTX ] has closed above bottom band by 35.0%. Bollinger Bands are 17.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.45 - 1.46 | 1.46 - 1.47 |
| Low: | 1.3 - 1.31 | 1.31 - 1.32 |
| Close: | 1.3 - 1.32 | 1.32 - 1.33 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Wed, 03 Apr 2024
Context Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer Therapy - MyChesCo
Mon, 01 Apr 2024
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers - Yahoo Canada Finance
Mon, 01 Apr 2024
Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers - Yahoo Finance
Mon, 01 Apr 2024
Where Does Context Therapeutics Inc (CNTX) Stock Fall in the Biotechnology Field After It Has Gained 21.37% This Week? - InvestorsObserver
Wed, 27 Mar 2024
Companies Like Context Therapeutics (NASDAQ:CNTX) Could Be Quite Risky - Yahoo Finance
Thu, 21 Mar 2024
Context Therapeutics Reports Full Year 2023 Operating and Financial Results - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 16 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 30 (%) |
| Shares Short | 11 (K) |
| Shares Short P.Month | 11 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -58.1 % |
| Return on Equity (ttm) | -102.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -21 (M) |
| Levered Free Cash Flow | -13 (M) |
| PE Ratio | -0.89 |
| PEG Ratio | 0 |
| Price to Book value | 1.78 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|